GlobeNewswire by notified

Grieg Seafood ASA: Share buy-back completed

Share

Grieg Seafood ASA's (the "Company") share buy-back program, announced on 21 December 2022 (the "Share buy-back"), is now completed.

Please see below information about transactions made under the Share buy-back. From 21 December 2022 until 30 December 2022, the Company has in total acquired 385,000 own shares at the Oslo Stock Exchange under the Share buy-back at an average share price of NOK 77.7643. Thus, the total consideration is NOK 29,939,237.53.

Aggregated overview of transactions per day:

DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)
21 December80,00077.38056,190,440.00
22 December80,00077.46926,197,536.00
23 December80,00077.12286,169,824.00
27 December39,98077.89393,114,198.12
28 December35,00077.92932,727,525.50
29 December50,02078.84553,943,851.91
30 December20,00079.79311,595,862.00
Totally acquired under the Share buy-back385,00077.764329,939,237.53

Following the transactions under the Share buy-back, the Company holds a total of 1,517,981 own shares, representing 1.3381% of the Company's share capital. As stated, the purpose of the Share buy-back has been to re-increase the number of own shares held as the Company has used own shares in connection with its share saving program for employees.

Attachment: An overview of all the completed transactions under the Share buy-back for all transaction dates is enclosed to this notification and available on www.newsweb.no.

Bergen, 30 December 2022.

For enquiries, please contact:

Atle Harald Sandtorv, CFO Cell phone +47 908 45 252


About Grieg Seafood
Grieg Seafood ASA is one of the world's leading salmon farmers. Our farms are in Finnmark and Rogaland in Norway, and British Columbia as well as Newfoundland in Canada. Our headquarter is located in Bergen, Norway. Grieg Seafood ASA was listed at the Oslo Stock Exchange in June 2007. More than 750 people work in the company throughout our regions.

Sustainable farming practices are the foundation of Grieg Seafood’s operations. The lowest possible environmental impact and the best possible fish welfare is both an ethical responsibility and drive economic profitability. Towards 2026, we aim for global growth, cost improvements and to evolve from a pure salmon supplier to an innovation partner for selected customers.

To learn more, please visit www.griegseafood.com.


This information is publicly disclosed in accordance with section 5-12 of the Norwegian Securities Trading Act as well as the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Adevinta (ASA) publishes its 2023 Annual Report26.4.2024 08:30:00 CEST | Press release

Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant growth in our Mobility, Re-Commerce and Real Estate & Emerging verticals, substantiating our focus in these areas. By putting technology and pr

PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release

Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en

Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding

STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil

Interim Report - January-March 202426.4.2024 08:00:00 CEST | Press release

STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company OssDsign reported positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst

Solvay publishes notice of 2024 Annual General Meeting26.4.2024 08:00:00 CEST | Press release

Brussels, April 26, 2024, 8:00am CEST - regulated information Solvay today published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May 28, 2024 at the Event Lounge Conference Center, Boulevard Général Wahis 16/F, 1030 Brussels, at 10.30 am CEST. All documents relating to this meeting are now available on www.solvay.com. Shareholders will be asked to vote on a number of resolutions, among others: the approval of the financial statements for the financial year 2023; the approval of a total gross dividend of €2.43 per share; the approval of the revised directors’ remuneration; the renewal of the mandate, for a four-year period, of Ms Aude Thibaut de Maisières, as Director of the company; the appointment of EY regarding the assurance of sustainability information imposed by the EU Directive on sustainability reporting (Corporate Sustainability Reporting Directive); the approval of the change of control provision relating to the issuance of eur

HiddenA line styled icon from Orion Icon Library.Eye